WG
RLAY icon

Winton Group’s Relay Therapeutics RLAY Stock Holding History

Winton Group’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,000
Closed -$135K – 1332
2025
Q4 		$135K Buy
+16,000
New +$114K ﹤0.01% 860
2021
Q4 		– Sell
-13,964
Closed -$440K – 1328
2021
Q3 		$440K Buy
13,964
+7,781
+126% +$262K 0.02% 926
2021
Q2 		$226K Buy
+6,183
New +$204K 0.01% 1302

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Winton Group's RLAY Position: Q1 2026 in Review

Winton Group sold out of Relay Therapeutics (RLAY) in Q1 2026, closing a stake of 16,000 shares — an estimated $135K sold.

Winton Group first reported a position in RLAY in Q2 2021 and held it in 3 quarters. The position peaked at $440K in Q3 2021. 244 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Winton Group reported no remaining Relay Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Winton Group sold 16,000 Relay Therapeutics shares in Q1 2026, an estimated $135K.
  • Winton Group first reported a position in Relay Therapeutics in Q2 2021 and held it in 3 quarters.
  • Winton Group's Relay Therapeutics position peaked at $440K in Q3 2021.
  • 244 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.